Medik8 Oxy-R Peptides is a potent brightening serum with a silky smooth feel (non-greasy). Designed to target hyperpigmentation, uneven skin tone and post-inflammatory redness from blemishes. This gentle get effective formula blocks the enzyme tyrosinase from forming further pigment in your skin, while fading your current pigmentation.
Supercharged, ultra brightening patented oxyresveratrol (oxy-R). For the first time ever stabilised at 1% – market leading strength. Combined with powerful twin brightening peptides, Oxy-R Peptides takes a triple threat approach to unwanted hyperpigmentation.
Suitable for
- Hyperpigmentation treatment.
- It is suitable for all skin types including sensitive skin.
Benefits of Medik8 Oxy-R Peptides
- Visibly fade dark spots, age spots and hyperpigmentation.
- Potent 1% Oxy-R technology with powerful twin-brightening peptides.
- Reduce uneven skin tone.
- Reduce hyperpigmentation following blemishes.
- Minimise the production of future melanin.
- Improved skin hydration.
- Free from; synthetic colour, Artificial fragrance, Parabens, Phthalate and Alcohol.
- Cruelty free and vegan friendly.
Medik8 Oxy-R Peptides Key Ingredients
- 1% Oxyresveratrol (Oxy-R)
One of the most powerful skin brightening agents available in skincare, which is naturally derived from the mulberry family. It helps to block the action of tyrosinase, to transform dull, uneven skin tones. - Tetrapeptide-30
An illuminating peptide that helps to minimise the production of tyrosinase, to block the overproduction of melanin. - Acetyl Glycyl Beta-Alanine
A brightening peptide solution that works to help block the transport of melanin to the skin cell, where the overproduction of pigment becomes visible on the skin. - Hyaluronic acid
With a unique ability to attract and retain more than 1,000 times its own weight in water, hyaluronic acid draws moisture from the surrounding atmosphere into the skin, leaving the complexion feeling both nourished and supple.
Medik8 Oxy-R Peptides 2 x 10ml bottles.
Reviews
There are no reviews yet.